Oncology

Latest News

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com

Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

By Jared Kaltwasser

June 19th 2025

Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of chemotherapy after progression following platinum-based chemotherapy.

The data presented at ASCO reflect patients seen during 2 community health fairs designed to reach underserved populations in Georgia. | Image credit: NIKCOA - stock.adobe.com

Teledermatology Shows Promise to Reduce Disparities in Skin Cancer Screening

By Jared Kaltwasser

June 18th 2025

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com

Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

By Jared Kaltwasser

June 13th 2025

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com

FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg

Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

By Giuliana Grossi

June 12th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

March 18th 2016

5 Key Takeaways From Cancerscape: ACCC's Meeting on Policy, Value, and Quality

Surabhi Dangi-Garimella, PhD

The 42nd annual meeting of the Association of Community Cancer Centers ensured that none of the oncology care providers in the audience left without realizing that healthcare has slowly been migrating to include value in care delivery and reimbursement decisions.

March 17th 2016

Painting a Picture of Cancer Cure Rates: Dr Alvarnas' PCOC15 Session

Joseph AlvarÂnas, MD, direcÂtor of value-based analytics at City of Hope, Duarte, California, and editor-in-chief of Evidence-Based Oncology painted an upbeat picture of cancer cure rates at the 2015 meeting of Patient-Centered Oncology Care.

March 17th 2016

Adverse Dermal Effects of PD-1 Inhibitors: Surrogate for Better Response?

Surabhi Dangi-Garimella, PhD

A new study in Australia adds to the evolving knowledge on adverse cutaneous effects of pembrolizumab and nivolumab. Could they also indicate better prognosis?

March 17th 2016

What We're Reading: Industry Money Linked to Increased Prescriptions of Brand Name Drugs

What we're reading, March 17, 2016: doctors who receive more industry money prescribe more brand name drugs; researchers project risk of Zika virus transmission in the US; and use of generic Gleevec could save $100,000 per patient.

March 17th 2016

Biosimilars Important in Management of Neutropenia

Recent analysis supports the potential importance of using biosimiliars of granulocyte colony stimulating factor to manage neutropenia affecting post-chemotherapy and post-op patients.

March 16th 2016

Telehealth for Melanoma? Dermatologists Prove It Is Possible

Surabhi Dangi-Garimella, PhD

Dermatologists have conducted a research study that proves "smartphone microscopes" can improve the detection of skin cancer in remote areas and in developing nations, where specialists are not as easily accessible to patients.

March 16th 2016

Atezolizumab: Another Novel IO Agent Faces Challenges With Enriching for Responders

Surabhi Dangi-Garimella, PhD

FDA has granted a Priority Review designation for the breakthrough programmed death ligand-1 inhibitor atezolizumab, for the treatment of bladder cancer.

March 16th 2016

Updated Guidelines Issued on Reducing Risk of Neutropenia in Patients With Cancer

Updated guidelines on the use of colony-stimulating factors (CSFs) in people with cancer address the strengths and limitations of the use of CSFs, which reduce the risk of neutropenia.

March 15th 2016

FDA Warns Against Idelalisib

Idelalisib has presented serious adverse events in combination trials in both the US and Europe.

March 15th 2016

Emerging Oncology Trends: A Chat With COA's Ted Okon

Laura Joszt, MA

At the end of February, Ted Okon, MBA, executive director of the Community Oncology Alliance (COA), answered questions on Twitter about the latest trends in cancer care and discussed COA’s concerns with the president’s moonshot initiative and the 340B drug pricing program.

March 15th 2016

US Healthcare System Needs a Revamp to Maintain Pace With Innovation: ASCO Report

Surabhi Dangi-Garimella, PhD

A new report published by the American Society of Clinical Oncology has drawn a mixed picture of oncology care in the United States-reduced mortality, increased survivors, and progress in treatment coupled with unsustainable costs and an unstable clinical setting.

March 14th 2016

Sorafenib and Sunitinib May Cause More Harm Than Good in Patients With RCC

Surabhi Dangi-Garimella, PhD

Two inhibitors of the vascular endothelial growth factor receptor approved for the treatment of metastatic renal cell cancer do not prevent cancer recurrence when used in the adjuvant setting following surgery, according to a new study in the Lancet.

March 14th 2016

TAPUR Study Promises Options for Patients With Advanced Cancer

Surabhi Dangi-Garimella, PhD

According to the American Society of Clinical Oncology, TAPUR provides patients access to drugs at no cost, and is designed to evaluate FDA-approved targeted agents for indications other than those on the drug’s label.

March 13th 2016

Provider Consolidation Increases Per-Person Spending

Increased medical provider consolidation with hospitals and/or health systems results in increased spending on outpatient prescription drug-based cancer treatment.

March 11th 2016

PhRMA's Policy Proposals Seek Innovation, but at What Cost?

Surabhi Dangi-Garimella, PhD

The proposals recommend modernizing policies across the healthcare industry, including the drug discovery and development process, promoting value-driven healthcare, increasing the consumer voice, and addressing market distortions.

March 10th 2016

Expert Advises Physicians on What to Expect From Medicare in 2016

Surabhi Dangi-Garimella, PhD

March 10th 2016

CVS Announces New Initiative, Commitment to a Tobacco-Free Generation

Surabhi Dangi-Garimella, PhD

Be The First is a 5-year, $50 million initiative to help deliver the nation's first tobacco-free generation.

March 9th 2016

ASCO, COA Unhappy With Proposed CMS Part B Reimbursement Model

Surabhi Dangi-Garimella, PhD

Several healthcare organizations have sent a letter to HHS urging withdrawal of this reimbursement model.

March 9th 2016

Cancer Deaths Drop, With Liver Cancer the Exception

The report found higher death rates from liver cancer among the age group most at risk for hepatitis C virus, those born between 1945 and 1965. But increased rates of diabetes, obesity, and alcohol use are to blame for rising liver cancer deaths as well.

March 9th 2016

Treating Diabetes Can Reduce a Woman's Risk for Breast Cancer

Surabhi Dangi-Garimella, PhD

A study conducted in Denmark identified an inverse association between controlling diabetes, through diet or oral medications, and breast density.

March 8th 2016

New Payment Model Will Test High-Value Prescription Drug Use Under Part B

Surabhi Dangi-Garimella, PhD

CMS has announced its plans to evaluate a new value-based payment model for prescription drugs covered under the Part B program. This is yet another move by the federal body to ensure quality care for Medicare enrollees.

March 8th 2016

Study Emphasizes Importance of Provider Communication in Easing Patient Anxiety

Surabhi Dangi-Garimella, PhD

Based on their survey results, the authors conclude that clinician communication following detection of pulmonary nodules can help bridge knowledge gaps and relieve stress.

March 8th 2016

21st Century Oncology Victim of Database Hack

21st Century Oncology has informed patients that their patient database was compromised late last year.

March 8th 2016

Family Members Prefer Compassionate End-of-Life Care for Cancer Patients

Surabhi Dangi-Garimella, PhD

Results of the study in JAMA underscore the importance of advance care planning.

March 7th 2016

Senators Take Up Case With FDA Following MSKCC Study

Surabhi Dangi-Garimella, PhD

Senators Amy Klobuchar (D-MN) and Jeanne Shaheen (D-NH) have sent a letter to the FDA urging the regulatory body to find efficient ways to distribute expensive cancer drugs.

March 7th 2016

Outdated Metrics in the Age of Precision Medicine

Panelists discussing quality metrics in oncology were not sure payment and federal policies could keep pace with what's happening on the front lines.

March 7th 2016

Panelists Predict FFS Will Grow More Cumbersome

CMS has attempted to tailor ACOs to meet a variety of needs and levels of risk, depending on where parties are in their knowledge level of payment reform.

March 7th 2016

Personalizing Melanoma Treatment Based on Patient Response

Surabhi Dangi-Garimella, PhD

By monitoring for mutations in the circulating tumor DNA of melanoma patients undergoing treatment, researchers at Cancer Research UK Manchester Institute are confident they can predict how patients will respond to their treatment and whether their disease would relapse.

March 7th 2016

Bridging the Communication Gap to Overcome "Financial Toxicity"

Yousuf Zafar, MD, MHS, found that most cancer patients would like to discuss financial concerns with their doctors, but few actually do, for a variety of reasons.

March 6th 2016

Putting Big Data to Work for Better Care in Oncology

Flatiron Health seeks to use data to prevent the patient experience from being lost.

...

107 108 109 110 111 112 113 114 115

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions